Access the full text.
Sign up today, get DeepDyve free for 14 days.
Detection of HER2/neu (c-erbB-2) DNA amplification in primary breast carcinoma
M. Coombes, Emma Ph.D., Lorna Ph.D., Robert M.Phil., Ph.D Jassem, Thierry Ph.D., Stephen M.D., Isabel M.D., M. Bertelli, Olaf M.D., Alan Ph.D., Emilio M.D., David M.D., M. Coleman, Lesley M.D., D.Phil, M. Mickiewicz, D.M.Sc Andersen, Per Lønning, Giorgio Ph.D., Alan Ph.D., Nick M.D., M.Sc Snowdon, Ph.D Carpentieri, M. Massimini, M.Sc Bliss (1977)
THE NEW ENGLAND JOURNAL OF MEDICINEThe Lancet, 309
C. Vogel, M. Cobleigh, D. Tripathy, J. Gutheil, L. Harris, L. Fehrenbacher, D. Slamon, M. Murphy, W. Novotny, M. Burchmore, S. Shak, S. Stewart, M. Press (2023)
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 41
H. Tsuda, F. Akiyama, H. Terasaki, T. Hasegawa, M. Kurosumi, M. Shimadzu, S. Yamamori, G. Sakamoto (2001)
Detection of HER‐2/neu (c‐erb B‐2) DNA amplification in primary breast carcinomaCancer, 92
L. Arnould, Y. Denoux, G. MacGrogan, F. Penault-Llorca, M. Fiche, I. Treilleux, M. Mathieu, A. Vincent-Salomon, M. Vilain, J. Couturier (2003)
Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancerBritish Journal of Cancer, 88
H. Kumamoto, H. Sasano, T. Taniguchi, Takashi Suzuki, T. Moriya, R. Ichinohasama (2001)
Chromogenic in situ hybridization analysis of HER‐2/neu status in breast carcinoma: Application in screening of patients for trastuzumab (Herceptin®) therapyPathology International, 51
N. Dandachi, O. Dietze, C. Hauser-kronberger (2002)
Chromogenic In Situ Hybridization: A Novel Approach to a Practical and Sensitive Method for the Detection of HER2 Oncogene in Archival Human Breast CarcinomaLaboratory Investigation, 82
S. Shak (1999)
Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.Seminars in oncology, 26 4 Suppl 12
M. Tanner, D. Gancberg, A. Leo, D. Larsimont, G. Rouas, M. Piccart, J. Isola (2000)
Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.The American journal of pathology, 157 5
C. Solomides, R. Zimmerman, M. Bibbo (1999)
Semiquantitative assessment of c-erbB-2 (HER-2) status in cytology specimens and tissue sections from breast carcinoma.Analytical and quantitative cytology and histology, 21 2
G. Troncone, P. Zeppa, F. Fulciniti, G. Benedetto, M. Lobresco, B. Divitiis, A. Vetrani, L. Palombini (1993)
C‐Erbb‐2 Expression and Dna Ploidy Status In Breast Cancer Cells Obtained By Fine Needle Aspiration (Fna)Cytopathology, 4
D. Slamon, G. Clark, S. Wong, W. Levin, A. Ullrich, W. McGuire (1987)
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science, 235 4785
(1972)
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2overexpressing metastatic breast cancer
G. Troncone, L. Panico, A. Vetrani, B. Divitiis, P. Zeppa, F. Fulciniti, G. Pettinato, L. Palombini (1996)
c‐erbB‐2 expression in FNAB smears and matched surgical specimens of breast cancerDiagnostic Cytopathology, 14
J. Ross, J. Fletcher (1999)
HER-2/neu (c-erb-B2) gene and protein in breast cancer.American journal of clinical pathology, 112 1 Suppl 1
(1993)
C-erbB-2 expression and DNA ploidy status in breast cancer cells obtained by fine needle aspiration
(1999)
Multinational study of the efficacy and safety humanized anti-HER2 overexpression in metastatic breast cancer that has progressed after chemotherapy for metastatic disease
(2001)
Detection of HER2/neu (c-erbB-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression
(1989)
Studies of the HER-2/ neu proto-oncogene in breast and ovarian cancer
M. Pegram, Sheree Hsu, G. Lewis, R. Pietras, Malgorzata Beryt, M. Sliwkowski, D. Coombs, D. Baly, F. Kabbinavar, D. Slamon (1999)
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancersOncogene, 18
Jianxin Zhao, R. Wu, A. Au, A. Marquez, Yibing Yu, Zuorong Shi (2002)
Determination of HER2 Gene Amplification by Chromogenic In Situ Hybridization (CISH) in Archival Breast CarcinomaModern Pathology, 15
D. Tiniakos, K. Robinson, H. Greenwood, P. Cullen, A. Cook, C. Horne, B. Angus (1996)
c‐erbB‐2 and p53 expression in breast cancer fine needle aspiratesCytopathology, 7
D. Gupta, L. Middleton, M. Whitaker, J. Abrams (2003)
Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer.American journal of clinical pathology, 119 3
L. Diaz, Rohit Gupta, Noman Kidwai, N. Sneige, E. Wiley (2004)
The Use of TMA for Interlaboratory Validation of FISH Testing for Detection of HER2 Gene Amplification in Breast CancerJournal of Histochemistry & Cytochemistry, 52
M. Corkill, R. Katz (1994)
Immunocytochemical staining of c‐erbB‐2 oncogene in fine‐needle aspirates of breast carcinoma: A comparison with tissue sections and other breast cancer prognostic factorsDiagnostic Cytopathology, 11
Overexpression of HER2 protein and HER2 gene amplification in breast cancer are prognostic factors for the response to specific medical treatments such as trastuzumab, endocrine therapy, and chemotherapy. Whereas HER2 expression and gene amplification are generally examined in tissue sections, we investigated whether specimens from fine needle aspiration cytology (FNAC) are adequate for these analyses. HER2 protein overexpression and HER2 gene amplification were assessed in both FNAC specimens and tissue sections from 58 cases of invasive breast cancer. Immunohistochemistry assay for HER2 protein expression was performed according to the HercepTest protocol, and HER2 gene amplification was examined with the Spot-light CISH (chromogenic in situ hybridization) Detection kit. There was a significant positive correlation between assessments of HER2 protein status in the cytology specimens and tissue sections. The sensitivity, specificity, and accuracy of HER2 gene amplification detection in cytology specimens in relation to those in tissue sections were 84.0% (21/25 cases), 87.9% (29/33 cases), and 86.2% (50/58 cases), respectively. FNAC specimens are suitable for detection of HER2 overexpression and HER2 gene amplification in invasive breast cancer.
Oncology Reports – Spandidos Publications
Published: Apr 1, 2006
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.